Eric Rivals (LIRMM’s MAB team) Winner of Le Point’s 2025 innovators award, with EpiTransDiag
Link: https://evenements.lepoint.fr/paris-saclay-summit/
Cyberna link: https://cyberna.com/
The project EpiTransDiag is honored to have been selected by a external jury (with plenty of distinguished scientists) in the category Technology for Medicine (MedTech). The Palmarès includes 100 laureates.
Thanks to our institutions:
the CNRS, the University of Montpellier, the IRCM – Institut de Recherche en Cancérologie de Montpellier), and the Montpellier University Hospital (CHU de Montpellier).
And to our labs: Christophe Hirtz (PPC Plateforme de Protéomique Clinique – Institut for Regenerative Medecine & Biothérapies (IRMB)), Alexandre David (IRCM) and my self at LIRMM.
In EpiTransDiag, we exploit chemical modifications of RNA using machine learning to diagnose cancer at early stages. Indeed, when diagnosed in the earliest stages of the tumor development, many cancers can be cured. It is critical to propose accurate techniques for early diagnostics. For this we leverage the power of mass spectrometry.
EpiTransDiag is the starting point of this adventure. Our project has given rise to the CYBERNA start-up, which will further develop this technology and turn it into cancer diagnosis tests.
The jury, the laureates of this year Palmarès, and more infos at:
https://lnkd.in/eG6_fmca
Thanks to SATT AxLR for funding this technology maturation project, and especially to Candice Perez, and Henri Piras. Thanks to CNRS Innovation, and especially Anne-Lou Touret for their support in the early days of EpiTransDiag.
Contact : rivals@lirmm.fr
